Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Xavier

Showing results (111-120 of 152) with videos related to

Pageof 16
Sort By:
European Heart Journal|May 8, 2021
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participantsJackie Bosch, Eva M Lonn, Hyejung Jung, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
Lancet (London, England)|August 16, 2025
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trialMichael Walsh, David Collister, Martin Gallagher, et al.
The Lancet Regional Health. Southeast Asia|December 19, 2022
An observational multi-centric COVID-19 sequelae study among health care workersAjay Kumar Shukla, Shubham Atal, Aditya Banerjee, et al.
The Canadian Journal of Cardiology|October 21, 2015
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline CharacteristicsEva Lonn, Jackie Bosch, Janice Pogue, et al.
Neuroepidemiology|May 5, 2021
Renal Impairment and Risk of Acute Stroke: The INTERSTROKE StudyAndrew Smyth, Conor Judge, Xingu Wang, et al.
The New England Journal of Medicine|April 5, 2016
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular DiseaseSalim Yusuf, Eva Lonn, Prem Pais, et al.
The New England Journal of Medicine|April 5, 2016
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseSalim Yusuf, Jackie Bosch, Gilles Dagenais, et al.
The Canadian Journal of Cardiology|February 6, 2018
Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE)Emmanuelle Duceppe, Salim Yusuf, Vikas Tandon, et al.
The Lancet. Respiratory Medicine|October 13, 2022
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trialJohn W Eikelboom, Sanjit S Jolly, Emilie P Belley-Cote, et al.
Pageof 16

Showing results (111-120 of 152) with videos related to

Sort By:
Pageof 16
European Heart Journal|May 8, 2021
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participantsJackie Bosch, Eva M Lonn, Hyejung Jung, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
Lancet (London, England)|August 16, 2025
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trialMichael Walsh, David Collister, Martin Gallagher, et al.
The Lancet Regional Health. Southeast Asia|December 19, 2022
An observational multi-centric COVID-19 sequelae study among health care workersAjay Kumar Shukla, Shubham Atal, Aditya Banerjee, et al.
The Canadian Journal of Cardiology|October 21, 2015
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline CharacteristicsEva Lonn, Jackie Bosch, Janice Pogue, et al.
Neuroepidemiology|May 5, 2021
Renal Impairment and Risk of Acute Stroke: The INTERSTROKE StudyAndrew Smyth, Conor Judge, Xingu Wang, et al.
The New England Journal of Medicine|April 5, 2016
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular DiseaseSalim Yusuf, Eva Lonn, Prem Pais, et al.
The New England Journal of Medicine|April 5, 2016
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseSalim Yusuf, Jackie Bosch, Gilles Dagenais, et al.
The Canadian Journal of Cardiology|February 6, 2018
Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE)Emmanuelle Duceppe, Salim Yusuf, Vikas Tandon, et al.
The Lancet. Respiratory Medicine|October 13, 2022
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trialJohn W Eikelboom, Sanjit S Jolly, Emilie P Belley-Cote, et al.
Pageof 16